Prediction of Response to the Anti-EGFR Antibody Panitumumab Combined with Standard Neoadjuvant Chemotherapy in Triple Negative Breast Cancer (TNBC): The Immune and IGFR Pathways

被引：0
|
作者：
Penault-Llorca, F.
Abrial, C.
Douplat, M-M
Privat, M.
Uhrhammer, N.
Desrichard, A.
Bidet, Y.
Radosevic-Robin, N.
Cayre, A.
Aube, C.
Kwiatkowski, F.
Bignon, Y-J
Chollet, P.
Nabholtz, J-M
机构：
[1] Ctr Jean Perrin, Clermont Ferrand, France
[2] Univ Auvergne, EA 4677 ERTICa, Clermont Ferrand, France
来源：
LABORATORY INVESTIGATION | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
254
引用
收藏
页码：63A / 63A
页数：1
相关论文
共 50 条
  • [31] Comprehensive immune profiling reveals factors associated with neoadjuvant chemotherapy response in triple negative breast cancer
    Seager, Robert
    Ko, Heidi
    Pabla, Sarabjot
    Senosain, Maria-Fernanda
    Kalinski, Pawel
    Van Roey, Erik
    Gao, Shuang
    Strickland, Kyle
    Previs, Rebecca
    Nesline, Mary
    Hastings, Stephanie
    Zhang, Shengle
    Conroy, Jeffrey
    Jensen, Taylor
    Eisenberg, Marcia
    Caveney, Brian
    Severson, Eric
    Ramkissoon, Shakti
    Gandhi, Shipra
    CANCER RESEARCH, 2024, 84 (09)
  • [32] Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer
    Kusama, Hiroki
    Kittaka, Nobuyoshi
    Soma, Ai
    Taniguchi, Azusa
    Kanaoka, Haruka
    Nakajima, Satomi
    Oyama, Yuri
    Seto, Yukiko
    Okuno, Jun
    Watanabe, Noriyuki
    Matsui, Saki
    Nishio, Minako
    Fujisawa, Fumie
    Honma, Keiichiro
    Tamaki, Yasuhiro
    Nakayama, Takahiro
    BREAST CANCER, 2023, 30 (06) : 1085 - 1093
  • [33] Humanized anti-EGFR antibody panitumumab inhibits tumor growth of inflammatory breast cancer by inducing antitumor immunity
    Wang, Xiaoping
    Shao, Shan
    Semba, Takashi
    Pearson, Troy
    Re, James M.
    Tripathy, Debu
    Ueno, Naoto
    CANCER RESEARCH, 2019, 79 (13)
  • [34] Efficacy and safety of Anlotinib based neoadjuvant chemotherapy for locally advanced triple negative breast cancer (TNBC)
    Ren, Kuojun
    Wang, Shuhan
    Ye, Tingbo
    Zhu, Zhengzhi
    Hong, Shikai
    Wang, Shengying
    Liu, Jianjun
    BMC CANCER, 2024, 24 (01)
  • [35] Early ultrasound evaluation for prediction of treatment response to neoadjuvant chemotherapy in triple negative breast cancer patients
    Adrada, B. E.
    Candelaria, R.
    Moulder, S.
    Lane, D.
    Santiago, L.
    Arribas, E.
    Hess, K. R.
    Valero, V.
    Thompson, A.
    Helgason, T.
    Ravenberg, E.
    Yang, W.
    Rauch, G. M.
    CANCER RESEARCH, 2019, 79 (04)
  • [36] The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).
    Abuhadra, Nour
    Chang, Chia-Chi
    Yam, Clinton
    White, Jason B.
    Ravenberg, Elizabeth
    Lim, Bora
    Ueno, Naoto T.
    Litton, Jennifer Keating
    Arun, Banu
    Damodaran, Senthil
    Murthy, Rashmi Krishna
    Ibrahim, Nuhad K.
    Hortobagyi, Gabriel N.
    Valero, Vicente
    Tripathy, Debu
    Thompson, Alastair Mark
    Mittendorf, Elizabeth A.
    Huo, Lei
    Moulder, Stacy L.
    Jenq, Robert R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study
    Gamucci, T.
    Mentuccia, L.
    Vici, P.
    Iezzi, L.
    Sperduti, I.
    Astone, A.
    Marchetti, P.
    Pizzuti, L.
    Michelotti, A.
    Sini, V.
    Cassano, A.
    Ciancola, F.
    Quadrini, S.
    Moscetti, L.
    Landucci, E.
    Sergi, D.
    Magnolfi, E.
    Natoli, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S315 - S315
  • [38] Which Imaging Modality Is Superior for Prediction of Response to Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer?
    Atkins, Jordan J.
    Appleton, Catherine M.
    Fisher, Carla S.
    Gao, Feng
    Margenthaler, Julie A.
    JOURNAL OF ONCOLOGY, 2013, 2013
  • [39] Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: a restrospective multicenter observational study
    Iezzi, L.
    Mentuccia, L.
    Vici, P.
    Natoli, C.
    Sperduti, I.
    Astone, A.
    Marchetti, P.
    Pizzuti, L.
    Michelotti, A.
    Sini, V.
    Cassano, A.
    Ciancola, F.
    Quadrini, S.
    Moscetti, L.
    Landucci, E.
    Magnolfi, E.
    Sergi, D.
    Gamucci, T.
    ANNALS OF ONCOLOGY, 2015, 26 : 7 - 7
  • [40] Transcriptomic modification induced by the first cycle of neoadjuvant chemotherapy impacts response to treatment in triple-negative breast cancer (TNBC)
    Desmoulins, I.
    Chardin, D.
    Richard, C.
    Arnould, L.
    Boidot, R.
    Humbert, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S494 - S494
12345